Американское общество гирудотерапии

Heparin-induced thrombocytopenia: a general review

Review published in J Infus Nurs (2007)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewРазработка лекарственных препаратовКлинические исследованияSwanson JM · Journal of infusion nursing, 2007

Abstract

Unfractionated heparin is widely used for numerous clinical situations. A well-known adverse effect of heparin exposure is thrombocytopenia. Heparin-induced thrombocytopenia is a clinicopathologic syndrome that can be associated with severe complications and significant mortality. The pathophysiology of heparin-induced thrombocytopenia includes an immune-mediated reaction to heparin that activates platelets and results in an acquired hypercoagulability. Diagnosis of heparin-induced thrombocytopenia should incorporate clinical signs and symptoms and laboratory testing for heparin-induced thrombocytopenia antibodies. Therapy should include discontinuation of heparin, initiation of a direct thrombin inhibitor, and eventually therapy with warfarin (only after the platelet count is at least 100 x 10(9)/L).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsArginineDrug MonitoringFactor Xa InhibitorsFondaparinuxHeparinHirudinsHumansNursing AssessmentPeptide FragmentsPipecolic AcidsPlatelet Activation

Резюме

Nursing-focused review of HIT diagnosis and management including DTI therapy initiation and warfarin transition once platelet count exceeds 100x10^9/L.

Почему это важно для гирудотерапии

This general review covers heparin-induced thrombocytopenia as a clinicopathologic syndrome, describing its immune-mediated pathophysiology, the importance of combining clinical assessment with laboratory antibody testing for diagnosis, and a treatment algorithm of heparin discontinuation, initiation of a direct thrombin inhibitor, and eventual warfarin transition only after platelet recovery to at least 100 × 10⁹/L. The abstract refers generically to direct thrombin inhibitors without naming lepirudin, hirudin, or any specific agent, and does not mention leeches or the leech secretome. Therefore, no specific relevance to hirudotherapy can be established from the abstract text, and the connection is at most indirect. The abstract provides no primary data and no hirudin-specific pharmacology or outcomes.

Цитирование

Heparin-induced thrombocytopenia: a general review.

Swanson JM · Journal of infusion nursing, 2007

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.